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Abstract
HSV-1 is an important epithelial pathogen and has the potential for significant morbidity in
humans. Here we demonstrate that a cell surface scavenger receptor, macrophage receptor with
collagenous structure (MARCO), previously thought to enhance antiviral defense by enabling
nucleic acid recognition, is usurped by HSV-1 and functions together with heparan sulfate
proteoglycans to mediate adsorption to epithelial cells. Ligands of MARCO dramatically inhibit
HSV-1 adsorption and infection of human keratinocytes and protect mice against infection. HSV-1
glycoprotein C (gC) closely co-localizes with MARCO at the cell surface, and gC binds directly to
purified MARCO with high affinity. Increasing MARCO expression enhances HSV-1 infection
while MARCO-/- mice have reduced susceptibility to infection by HSV-1. These findings
demonstrate that HSV-1 binds to MARCO to enhance its capacity for disease, and suggests a new
therapeutic target to alter pathogenicity of HSV-1 in skin infection.
Introduction
HSV-1 infections are a frequent occurrence and have the potential to develop into life-
threatening disease in immunocompromised individuals. Primary infection typically begins
in the skin and mucocutaneous regions by targeting keratinocytes, the most abundant cell
type in these tissues. If infection is not controlled, HSV-1 can spread to other target organs
including the central nervous system (CNS). Despite advances in antiviral therapies that
have reduced HSV morbidity and mortality, it remains of considerable interest to understand
in greater detail the elements contributing to HSV-1 virulence. Towards this end, a more
detailed analysis of the host elements that are used by the virus to promote infection and the
local elements of the mucocutaneous defense system that act to resist HSV-1 infection is
needed.
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HSV-1 initiates disease by repurposing host-derived molecules to enhance its virulence. The
first step in this process is adsorption of the virus to the cell surface. Heparan sulfate
proteoglycans (HSPGs) were the only known molecules on the host cell responsible for this
process1. Interestingly, HSV-1 and HSV-2 both bind to HSPGs yet recognize different
structural features of heparan sulfate, thus showing that there is some degree of specificity to
this interaction2. Glycoprotein C (gC) is the major HSV-1 glycoprotein that binds to
HSPGs3, 4, but glycoprotein B (gB) also contributes to HSPG adsorption, and this is
particularly important in the absence of gC5. The HSPGs Syndecan-1 and Syndecan-4 are
highly expressed by keratinocytes6 and may serve as adsorption receptors for HSV-1,
however studies have not addressed which specific receptors expressed by keratinocytes are
most vital for adsorption. Membrane fusion events follow adsorption and additionally
involve interactions of HSV-1 glycoprotein D (gD) and gB with the cell surface. Multiple
cell surface targets have been identified for viral entry including for gD: 3-O-sulfated
heparan sulfate7, tumor necrosis factor receptor superfamily member 14 (commonly known
as HVEM)8, or poliovirus receptor-related protein 1 (commonly known as Nectin-1)9, and
for gB: paired immunoglobulin-like type 2 receptor alpha10 or myosin-9 (also known as
non-muscle myosin IIa)11.
To mount an effective antiviral response cells must recognize the virus and initiate an
appropriate immune response. Several types of innate immune receptors have been
associated with the capacity to detect HSV infection12. Class A scavenger receptors are an
important element in this innate immune detection process as they bind to extracellular viral
dsRNA at the cell surface to mediate dsRNA uptake and to enable this dsRNA to interact
with TLR3 in the endosome13-17. Failures of this TLR3-dependent innate immune
recognition pathway can have serious consequences. For example, human patients with
genetic defects in TLR318, and other proteins involved in mediating the TLR3-dependent
response to dsRNA19-21, are predisposed to herpes simplex encephalitis, a severe,
disseminated infection of the CNS, and TLR3 deficiency in mice renders astrocytes more
susceptible to HSV infection and leads to HSV-mediated disease in the CNS22. It is
hypothesized that TLR3 is important for recognition of a DNA virus such as HSV-1 because
virtually all viruses produce dsRNA during replication23, and this dsRNA is released into
extracellular space following lysis of infected cells24. Thus, cells expressing TLR3 have the
ability to defend against HSV-1 by using this receptor to respond to dsRNA, and this
appears to be particularly crucial to innate antiviral defense in the CNS.
Here, we present the unexpected discovery that instead of contributing to host defense, the
class A scavenger receptor MARCO is exploited by HSV-1 to promote cell surface
adsorption and infection in the skin.
Results
Scavenger receptor ligands inhibit HSV-1 infection
Surface epithelial cells are the initial target for viral entry and can activate a potent innate
immune response through TLR325-28. Activation of TLR3 increases pro-inflammatory
cytokines, antimicrobial peptides and IFNs in skin and other tissues29-31, and has been
frequently linked with cutaneous immune and antiviral responses25, 32, 33. We first sought to
determine whether activation of TLR3 could enable keratinocytes to directly defend
themselves against HSV-1 by treating cells with Poly(I:C), a synthetic dsRNA25-28.
Poly(I:C) treatment resulted in inhibition of HSV-1 infection as assessed by measuring
levels of HSV-1 gD mRNA (Fig. 1a). However, TLR3 activation appeared to be dispensible
for this protection against infection since treatment with Poly(I), a ssRNA component of
Poly(I:C) that does not activate TLR3, conferred protection against HSV-1 similar to that
seen with Poly(I:C) (Fig. 1a). Poly(I) and Poly(C) were not able to increase expression of
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IL-6, IL-8, IFN-β and human beta-defensin 2 (hBD-2), four genes that were significantly
increased by Poly(I:C) stimulation of normal human epidermal keratinocytes (NHEK) (Fig.
1b). Furthermore, inhibition of IFN-β production by methylthioadenosine (MTA)34, a Signal
Transducers and Activators of Transcription 1 (STAT1) inhibitor, did not alter the capacity
of Poly(I:C) to reduce HSV-1 gD expression (Supplementary Fig. S1a,b). These results
indicated that although IFN-β has well-characterized antiviral effects35, 36, it was not
responsible for protection against HSV-1 infection by Poly(I:C) under these conditions. We
confirmed these results by utilizing chloroquine (CQ) to more directly examine the effect of
TLR3 inhibition on the ability of Poly(I:C) to protect against HSV-1 infection, as CQ is
known to be a potent inhibitor of endosomal acidification and TLR3 activation16. As
expected, pretreatment with CQ inhibited the capacity of Poly(I:C) to stimulate expression
of IL-6 and IFN-β, thus confirming that TLR3 activation was inhibited (Supplementary Fig.
S1c). However, despite inhibition of cytokine and interferon responses, CQ did not reduce
the capacity of Poly(I:C) to protect against HSV-1 infection (Supplementary Fig. S1d),
further showing that cellular activation mediated by TLR3 was not required for the
protective effects of Poly(I:C). Therefore, since Poly(I) was capable of inhibiting HSV-1
infection, but Poly(C) was not, we considered alternate explanations that could account for
the antiviral activity of both Poly(I) and Poly(I:C).
Both Poly(I) and Poly(I:C) are ligands for class A scavenger receptors, a family of cell
surface molecules required for dsRNA uptake prior to cell activation13-15, 37. Poly(C), which
did not protect against HSV-1, is not a ligand for class A scavenger receptors. Therefore, we
next hypothesized that the capacity to inhibit infection was related to the ability to bind
scavenger receptors. To test this hypothesis we examined additional scavenger receptors
ligands: Fucoidan (Fn) and dextran sulfate (Dxs). These were chosen since they also bind
scavenger receptors37 but are structurally distinct from the polynucleotides. The capacity of
Dxs, Fn, and Poly(I) to bind scavenger receptors was confirmed by showing their ability to
block Poly(I:C) stimulation of cytokine release (Supplementary Fig. S1e,f). Chondroitin
sulfate (CS) was used as a control for Dxs and Fn as it is another sulfated polysaccharide,
but like Poly(C) it cannot bind scavenger receptors, and had no effect on the capacity of
Poly (I:C) to function (Supplementary Fig. S1f).
Diverse molecules that share the capacity to bind scavenger receptors (Poly(I), Dxs and Fn)
all reduced HSV-1 plaque formation, but similar control molecules CS and Poly(C) did not
(Fig. 1c). However, heparin also inhibited HSV-1 infection in NHEK (Fig. 1c). This effect
was previously known and thought to occur by inhibiting the interaction of HSV-1 with cell
surface HSPGs1. Therefore, we next examined if scavenger receptor ligands might act by
interference with adsorption to HSPGs. To first test this, we compared the capacity of
Poly(I) and heparin to inhibit infection by a mutant form of HSV-1 that has a truncated gC
lacking amino acids 33-123, the C5/P domain (gCΔC5/P) predominantly responsible for
heparin binding4, 38. As expected, heparin treatment inhibited infection of WT virus but had
a less potent inhibitory effect on the mutant virus lacking this heparin binding domain (Fig.
1d). However, Poly(I) similarly inhibited infection of both the WT virus and the gCΔC5/P
mutant. These results, together with our previous findings, led us to hypothesize that HSV-1
infection of keratinocytes involves a previously unsuspected interaction with both a
scavenger receptor and HSPGs acting together to mediate adsorption to keratinocytes.
Scavenger receptor ligands inhibit HSV-1 and gC adsorption
We next tested the action of scavenger receptors ligands in the initial adsorption of HSV-1
to cell surfaces. Poly(I) prevented adsorption of whole HSV-1 viral particles to keratinocytes
in a dose-dependent manner, while increasing doses of Poly(C) had no effect (Fig. 2a). Since
adsorption of HSV-1 to the cell surface is primarily mediated by the viral glycoprotein
gC3, 4, we next analyzed the effects of Poly(I) on binding of this purified protein to the
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keratinocyte surface. The association of purified gC with NHEK was inhibited by Poly(I),
but not Poly(C) (Fig. 2b). Furthermore, as predicted from prior work, heparin blocked the
association of gC with cell surface HSPGs1 (Fig. 2b). However, Poly(I) inhibited binding of
gC by a different mechanism than heparin because Poly(I) could not displace gC from a
heparin column (Fig. 2c). In contrast, gC was easily displaced from heparin by sodium
chloride concentrations below 1.0 M (Fig. 2d), suggesting a relatively weak ionic
interaction. These results show that HSV-1 gC binds to keratinocytes by both heparan
sulfate-dependent and heparan sulfate-independent mechanisms, and Poly(I) acted on the
heparan sulfate-independent binding event.
MARCO co-localizes with HSV-1 virions and purified gC
We next sought to identify a specific scavenger receptor on keratinocytes that could
associate with HSV-1 gC. Analysis of NHEK determined that these cells express multiple
scavenger receptors including MARCO, OLR1, and SCARA3 (Supplementary Fig. S2).
These receptors can all bind Poly(I)39-42, and thus we sought to determine if these receptors
could co-localize with HSV-1 bound to the cell surface. To specifically measure co-
localization with HSV-1 gC, we employed a proximity ligation assay (PLA) that is designed
to generate a fluorescent signal only when the antigens tested reside within less than
approximately 40nm from one another. Assays were performed by maintaining cells at 4°C
to inhibit glycoprotein uptake and viral entry, and comparisons were made between co-
localization of HSV-1 gC with MARCO, syndecan-1, OLR1, and SCARA3. Syndecan-1, an
HSPG previously linked to HSV-1 infection43, 44, generated a positive PLA signal in the
presence of gC (Fig. 3b), confirming that this HSPG co-localized with gC. MARCO also
generated a strong positive PLA signal (Fig. 3a), indicating that MARCO and gC are
residing on the surface of the cells in close physical proximity in the absence of other viral
components. OLR1 and SCARA3, although abundantly expressed on the cell surface
(Supplementary Fig. S2), did not co-localize with HSV-1 gC (Fig. 3c,d). Similarly, when
whole virions were added instead of glycoprotein, a strong PLA signal was generated with
either MARCO or syndecan-1, but not OLR1 or SCARA3 (Supplementary Fig. S3),
confirming the selective, close co-localization of MARCO and syndecan-1 with HSV-1 gC.
MARCO directly binds to HSV-1 gC
The experiments described above implied that MARCO can interact directly with HSV-1
gC. We next used purified MARCO to verify that gC can bind to this protein in the absence
of other cellular receptors and to determine the affinity of this interaction. gC bound at nM
concentrations to MARCO, to saturation, and with association plots suggesting single order
specific binding (Fig. 4a,b). This effect was specific to gC and MARCO, as another viral
glycoprotein, gB, did not bind to MARCO (Fig. 4c), and gC did not bind to an alternative
scavenger receptor, OLR1 (Fig. 4d). Notably, the interaction between MARCO and gC had
a KD of 7.7×10-10 nM, a stronger affinity than that reported previously between gC and
heparan sulfate or heparin (KD values of 1.3×10-8 nM and 1×10-7 nM, respectively, obtained
by surface plasmon resonance)38.
Further evidence that HSV-1 gC adsorption to scavenger receptors is independent of
adsorption to HSPG was seen by analysis of binding to gC lacking the heparin binding (C5/
P) domain (amino acids 33-123). This truncated form of gC binds heparin with
approximately 42-fold lower affinity than the intact form of gC38 but still bound to MARCO
with relatively high affinity (Fig. 4e,f). The capacity of gC lacking the C5/P domain to bind
to MARCO was consistent with our earlier finding that the infectivity of HSV-1 harboring
this mutated gC was strongly inhibited by Poly(I), while heparin had a less potent inhibitory
effect compared to its capacity to inhibit infection by WT virus (Fig. 1f).
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HSV-1 infection correlates with MARCO expression
To confirm the functional significance of the interaction of HSV-1 gC and MARCO, we
next generated a HaCat keratinocyte cell line that stably overexpressed human MARCO.
MARCO overexpressing cells expressed approximately 3-fold more MARCO protein than
control cells (Fig. 5a,b, and Supplementary Fig. S4). Keratinocytes overexpressing MARCO
were more susceptible to infection than a control cell line (Fig. 5c,d), demonstrating that
increasing the expression of MARCO resulted in increased infection by HSV-1.
Furthermore, the presence of gC was essential for this enhancement of infection, as a mutant
virus lacking gC exhibited comparable levels of infection in control and MARCO
overexpressing cells (Fig. 5c,d).
Next, to test the relevance of disruption of scavenger receptors using an in vivo system, we
employed a model of severe cutaneous HSV-1 infection and tested the capacity of Poly(I) to
prevent HSV-1-mediated disease. Mice were immunocompromised by prior systemic
cyclophosphamide treatment45, then infected with HSV-1 in the skin. Mice were treated
locally with PBS, Poly(C) or Poly(I). Control mice treated with PBS or Poly(C) developed
large necrotic skin lesions, but Poly(I) treatment significantly inhibited cutaneous lesion
development (Fig. 5e).
Finally, to confirm the role of MARCO in this in vivo model and demonstrate the functional
relevance of the interaction of HSV-1 and MARCO, we compared infection in wildtype
(WT) and MARCO-/- mice. Skin lesions in WT mice were larger than those seen in
MARCO-/- mice, a difference that persisted and increased over the course of the experiment.
By day 8 post-infection MARCO-/- mice had 71% smaller skin lesions than WT controls
(Figure 5f, P<0.01, Two-way ANOVA).
Together, these findings indicate that the interaction of HSV-1 gC and MARCO is
functionally significant in HSV-1 infection and is relevant to cutaneous HSV-1 disease.
Discussion
We demonstrate using several independent lines of evidence that HSV-1 enhances
adsorption and infection of keratinocytes by binding the scavenger receptor MARCO.
Observations supporting this conclusion include competition experiments showing that the
scavenger receptor ligand Poly(I) inhibited adsorption and infection of HSV-1 in cultured
keratinocytes, inhibited purified gC binding to the cell surface, and inhibited HSV-1
infection in mouse skin. Furthermore, proximity ligation unambiguously detected the
physical co-localization of HSV-1 gC and MARCO on cells, and analysis of binding showed
direct high-affinity binding between MARCO and gC in cell free systems. Finally,
overexpression of MARCO in keratinocytes increased susceptibility to infection while
MARCO-/- mice were less susceptible to infection by HSV-1. Taken together, these findings
show for the first time that MARCO expression on keratinocytes contributes to early
infectious steps of HSV-1 in skin.
Our results demonstrate that HSV-1 adsorption to keratinocytes involves more than just an
interaction with HSPGs. We confirmed the previously reported1 role of HSPGs in
adsorption of HSV-1 since heparin was able to suppress gC binding and HSV-1 infection of
keratinocytes. Syndecan-1, an HSPG that is highly expressed on the surface of
keratinocytes, co-localized with gC and is the likely candidate for the HSPG to which gC
binds. However, although previous studies have shown that HSV-1 infection can still occur
in the absence of any cell surface HSPGs46, it was entirely unsuspected that the virus could
usurp a scavenger receptor to promote adsorption. We have now demonstrated that gC co-
localizes with MARCO and HSPGs on the cell surface, and gC bound directly to MARCO
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in the absence of other cellular or viral proteins. Interestingly, the affinity of gC to MARCO
appeared to be measurably higher than the previously known binding affinity of gC to
heparan sulfate. Furthermore, gC used distinct domains to bind to HSPGs and MARCO,
because deletion of the C5/P (heparin binding) domain dramatically reduced gC binding to
heparin but not to MARCO, and a mutant virus lacking the heparin binding domain
remained susceptible to inhibition by Poly(I). Previously, both dextran sulfate and fucoidan
were reported to be inhibitors of HSV-1 infection47. It was assumed that these compounds
inhibited infection by preventing interaction of HSV-1 with HSPGs, however both
compounds had substantially lower minimum inhibitory concentrations than heparin, and it
was not suspected that dextran sulfate or fucoidan might also have acted against HSV-1 by
competition with MARCO. Our results now suggest that the potent inhibitory of effects of
these compounds may result from their capacity to block interactions with both HSPGs and
MARCO. Thus, multiple lines of evidence show low affinity, high abundance (HSPGs) and
high affinity, low abundance (MARCO) receptors are binding to gC and acting together to
mediate adsorption and infection of keratinocytes.
Beyond promoting adsorption and infection, the interaction with MARCO may also benefit
HSV-1 by potentially enabling it to limit and evade innate immune responses. The binding
of HSV-1 to MARCO may interfere with the function of MARCO to endocytose nucleic
acids, thereby limiting the ability of cells to respond to exogenous nucleic acids via
intracellular innate immune receptors like TLR3. Additionally, a recent study has indeed
shown that although MARCO increases intracellular TLR recognition of nucleic acids, the
presence of these receptors actually has the opposite effect on the ability of cell-surface
TLRs to detect pathogens48. Thus, the interaction of HSV-1 with MARCO may increase
adsorption and also limit cell-surface recognition of viral components by alternative innate
immune receptors such as TLR2, which is also involved in the detection of HSV-149.
Further studies will be needed to evaluate the full consequences of the interaction of HSV-1
with MARCO.
From a clinical standpoint, the protection conferred against HSV-1 infection by scavenger
receptor ligands, and the significant reduction in infection in MARCO-/- mice, validated the
physiological relevance of our observations. Although the role of gC in viral attachment in
vitro has been well established, the complete virulence mechanism of gC in vivo is more
complex than this binding interaction. Ultimate virulence involves several factors such as
complement and antibody evasion, not only attachment50. The mouse model system used
here employed scarification as a method to increase access to keratinocytes and to enhance
local infection and amplification of the virus before spread to sensory ganglia51. These
results showed in vivo that access to MARCO is required for optimal infection in the skin.
However, it is not clear what role MARCO plays in infection of other tissues. The efficacy
of Poly(I) to inhibit HSV-1 infection in vivo was less than the effect seen on isolated
keratinocytes in in vitro, and the reduction seen in MARCO-/- mice was not absolute.
Further studies are needed to optimize treatment conditions to specifically block the multiple
modes by which HSV-1 adsorbs to keratinocytes. Such therapies can be especially useful in
diseases such as atopic dermatitis where epidermal susceptibility to viral infections is
enhanced.
Previous studies have shown that there are redundancies in the affinity and function of
scavenger receptors in nucleic acid uptake14, 15, and the role of other scavenger receptors in
HSV-1 infection is not clear. Using a different route of infection (intravenous), Suzuki et al.
previously reported that MSR1 knockout mice were more susceptible to HSV-1 infection
compared to WT mice52. This raises the important possibility that the role of scavenger
receptors might be specific to the route of administration, the type of receptor, and the cell
target. Since the subsequent recognition of viral nucleic acids by scavenger receptors is
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necessary for the later interferon response, it is possible that the observations with MSR1
deficient mice highlight the later immune defense role of this molecule. Future studies will
be needed to fully understand the outcome of the interaction of HSV-1 with scavenger
receptors and determine if these interactions are ultimately beneficial for the host or the
virus.
Some additional viruses have been previously suggested to interact with class A scavenger
receptors. For example, MSR1 has been shown to be essential to the sensing of HCMV by
endosomal TLRs17, indicating a protective role for MSR1 in this context. In contrast,
Adenovirus type 553 has been recently shown to use MSR1 to facilitate infection.
Additionally, it has been recently demonstrated that the presence of MARCO increases
susceptibility to influenza, although MARCO does not enhance viral uptake and instead
appears to suppress a beneficial early inflammatory response in the lungs54. Combined with
our current study, these results emphasize the nuanced relationship existing between class A
scavenger receptors and viruses.
To our knowledge this is the first demonstration that HSV-1 can utilize a component of the
pattern recognition system to enhance disease. Our studies concur with other examples of
HSV-1 modulating innate and adaptive immune systems to enhance virulence, but conflict
with the current common understanding of epithelial immune defense systems that predicts
that these elements are beneficial to the host55, 56, or that association with viral recognition
systems leads to protection against infection57, 58. Exploitation of the cell surface scavenger
receptor system by HSV-1 further illuminates the complexity of the interactions between the
host and pathogen at the epithelial surface.
Methods
Cells and animals and viruses
NHEK (Life Technologies, Grand Island, NY) were cultured in Epilife media containing
Epilife Defined Growth Supplement (Life Technologies, Grand Island, NY), 0.06mM
calcium chloride, and 100 I.U. Penicillin and 100μg Streptomycin per ml (VWR, Radnor,
PA). BSC-1 cells (ATCC, Manassas, VA) and HaCat keratinocytes (a gift from Rivkah
Isseroff, University of California, Davis) were cultured in DMEM (Lonza, Basel,
Switzerland), 10% FBS (Thermo Fisher Scientific, Waltham, MA), 2mM L-glutamine and
100 I.U. Penicillin and 100μg Streptomycin per ml (VWR, Radnor, PA). HaCat cells stably
overexpressing MARCO and control HaCat cells were generated by transfecting HaCats
with a pcDNA3 control plasmid or pcDNA3[MARCO], using the Nucleofector kit V and
Nucleofector device (Lonza, Basel, Switzerland). Cells were cultured for 3 weeks in media
containing 500μg/ml G418 (Biopioneer, San Diego, CA) to select for transfected cells prior
to use in experiments. These cells were continuously cultured in 500μg/ml G418 during
experiments. C57Bl/6 wildtype mice were purchased from the Jackson Laboratory, Bar
Harbor, Maine. MARCO-/- mice were a gift from Dr. Andrij Holian (Univerity of Montana,
MT). All animal studies were in accordance with the Public Health Service Policy on
Humane Care and Use of Laboratory Animals, and were approved by UCSD IACUC
(UCSD Animal Welfare Assurance # A3033-1). All procedures were performed under
isofluorane anesthesia, and all efforts were made to minimize pain, discomfort, and
suffering. The NS strain of HSV-1 (Fig. 1c,d, and Fig. 5c,d,f), the gCΔC5/P mutant (Fig.
1f), and the gC Null mutant (Fig. 5c,d) were a generous gift from Dr. Harvey Friedman
(University of Pennsylvania, PA). The Schooler strain of HSV-1 was a generous gift from
Dr. William Fenical (Scripps Institute of Oceanography, CA).
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Plasmids
A plasmid with a pcDNA3 backbone, expressing full-length human MARCO driven by a
CMV promoter, and a Neomycin resistance gene, pcDNA3[MARCO] (a gift from Sanjunkta
Ghosh, Harvard University, Boston MA) was used for transfection experiments, with
pcDNA3.1(-) (Life Technologies, Grand Island, NY) as a negative control plasmid.
Reagents and Primary Antibodies
Poly(I:C) was purchased from Invivogen, San Diego, CA. Poly(I), Poly(C), Dextran Sulfate,
Fucoidan, Chondroitan Sulfate, Heparin, cyclophosphamide, and methylthioadenosine was
purchased from Sigma-Aldrich, St. Louis, MO. Chloroquine phosphate was purchased from
Spectrum, Gardena, CA. Recombinant OLR1 was purchased from R&D Systems,
Minneapolis, MN. Purified HSV-1 gC (gC1(457t)), gB (gB1(730)), and gC(Δ33-123t)
(lacking the ΔC5/P domain) were generous gifts from Dr. Roselyn Eisenberg and Dr. Gary
Cohen (University of Pennsylvania, PA). A cell line for the production of recombinant
MARCO was kindly provided by Dr. Andrij Holian (Univerity of Montana, MT). MARCO
protein was produced and purified as described59. Primary antibodies recognizing HSV-1
gC (mouse monoclonal, clone T96, catalogue #sc-51626), HSV-1 gB (mouse monoclonal,
clone 10B7, catalogue #sc56987), MARCO (rabbit polyclonal, catalogue #sc-68913), OLR1
(rabbit polyclonal, catalogue #sc20753) and all IgG controls were purchased from Santa
Cruz Biotechnology, Santa Cruz, CA. A monoclonal primary antibody recognizing HSV-1
gD (clone 2C10, catalogue #ab6507) was purchased from Abcam, Cambridge, MA. A
primary antibody recognizing Syndecan-1 was previously characterized6. A rabbit
polyclonal antibody recognizing human SCARA3 (catalogue #SAB2700220) was purchased
from Sigma-Aldrich, St. Louis, MO. A mouse monoclonal antibody recognizing human
MARCO was previously characterized60. A rat monoclonal antibody recognizing mouse
MARCO (clone ED31, catalogue #MCA1849) was purchased from Hycult Biotech,
Plymouth Meeting, PA. A monoclonal antibody recognizing human GAPDH (clone 6C5,
catalogue #10R-G109a) was purchased from Fitzgerald, Acton, MA.
Fluorescence Microscopy
Cells were fixed with paraformaldehyde and blocked with 3% bovine serum albumin
(Sigma-Aldrich, St. Louis, MO). Prolong DAPI anti-fade and fluorescent Alexa Fluor
conjugated secondary antibodies (1:200 dilution) were used (Life Technologies, Grand
Island, NY). Images were captured using a BX41 microscope (Olympus, Center Valley,
PA).
Plaque Assay
Keratinocytes were infected with HSV-1 for two hours, then washed and incubated in fresh
media for 48 hours. Cells were fixed and plaque formation visualized by staining cells with
the anti-gD antibody (1:1,000), and an IR-Dye conjugated secondary antibody (1:10,000)
(LI-COR Biosciences, Lincoln, NE) and imaging stained plaques using an Odyssey Imager
(LI-COR Biosciences, Lincoln, NE). MOIs selected resulted in approximately 100-200
plaques per well in a 6-well plate using WT HSV-1, NS strain.
Quantitative real-time PCR
RNA and DNA were isolated using Trizol (Life Technologies, Grand Island, NY). RNA was
reverse transcribed using iScript (Bio-Rad, Hercules, CA). Predesigned Taqman probes and
primers were used to quantify IL-6, IL-8, hBD2 and IFN-β mRNA using Taqman Gene
Expression Master Mix and a 7300 Real Time PCR System (Life Technologies, Grand
Island, NY) according to manufacturer's instructions. Custom Taqman Probes (Life
Technologies, Grand Island, NY) were used for HSV-1 gD and GAPDH RNA and DNA
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quantification. HSV-1 gD probe: FAM-CCATACCGACCACACCGACGAACC-MGB;
GAPDH probe: VIC-CATCCATGACAACTTTGG TA-MGB. Primers sequences (Sigma-
Aldrich, St. Louis, MO): HSV-1: 5’-CGGCCGTGTGACACTATCG-3’, 5’-
CTCGTAAAATGGCCCCTCC-3’; GAPDH: 5’-CCTAGCACCCCTGGCCAAG-3’, 5’-
TGGTCATGAGTCCTTCCACG-3’. Fold change normalized to host cell GAPDH levels
relative to the control was calculated using the 2(-ΔΔCt) method.
ELISA
IL-6 concentration was determined using an OptEIA ELISA Set (BD Biosciences
Pharmigen, San Diego, CA).
HSV-1 Immunofluorescence Adsorption Assay
HSV-1 was incubated with cells at 4°C for 2 hours, then cells were washed to remove
unbound virus, fixed with paraformaldehyde, and stained using an HSV-1 gC antibody
(1:100), and an Alexa-Fluor labeled secondary antibody (1:200) (Life Technologies, Grand
Island, NY). Images were taken by fluorescent microscopy (described above) and HSV-1
particles were quantified using ImageJ. The specificity of this assay was validated by control
experiments using serial diluted HSV-1.
Western Blot
Protein was isolated by lysing cells at 4°C in 1X RIPA buffer containing protease inhibitors
(Roche, Basel, Switzerland) and protein concentrations quantified using a BCA assay
(Thermo Fisher Scientific, Waltham, MA). 20μg total protein was loaded on a 4-20%
agarose gel and transferred to a PVDF membrane (Bio-Rad, Hercules, CA). MARCO
protein was detected using the rabbit polyclonal antibody (1:1,000) and GAPDH was
detected using the mouse monoclonal antibody (1:10,000). 680nm and 800nm IR-Dye
conjugated secondary antibodies (1:10,000) and an Odyssey imager and quantification
software (LI-COR Biosciences, Lincoln, NE) were used for 2-color western blotting to
analyze both proteins on the same blot.
On-cell Western gC cell binding assay
gC was incubated with cells and the indicated compounds together at 4°C. Cells were
washed before fixation. Bound gC was detected with the anti-gC antibody (1:100) and an
IR-Dye conjugated secondary antibody (1:800) (LI-COR Biosciences, Lincoln, NE), and an
Odyssey imager (LI-COR Biosciences, Lincoln, NE). A standard curve was generated using
serial dilutions of known concentrations of gC bound to cells to quantify the amount of
bound gC.
ELISA binding assay
Capture protein was bound to EIA/RIA plates (Thermo Fisher Scientific, Waltham, MA) in
PBS lacking calcium and magnesium, pH 7.4 (Life Technologies, Grand Island, NY),
blocked with PBS containing 3%BSA (Sigma-Aldrich, St. Louis, MO), then incubated with
viral glycoproteins diluted in PBS. Cells were washed with PBS containing 0.05%
Tween-20. Bound glycoproteins were detected using primary antibodies (1:200), HRP-
conjugated secondary antibodies (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA), and
TMB substrate reagent (BD Biosciences Pharmigen, San Diego, CA). Standard curves for
quantification of bound viral glycoproteins were generated using serial dilutions of known
concentrations of the proteins.
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HPLC
A HiTrap Heparin HP Column and AKTA purifier HPLC system (GE Healthcare,
Piscataway, NJ) were used for analysis. Briefly, 100μg of purified gC protein was loaded on
to the heparin column and the column was washed to remove any unbound gC. Freshly
prepared Poly(I) and NaCl solutions were used to generate the indicated concentration
gradients used for elution. 1ml fractions were collected during the elution, and the amount of
gC present in these fractions was quantified by dot blot using the anti-gC antibody (1:1,000),
an IR-Dye conjugated secondary antibodies (1:10,000) (LICOR Biosciences, Lincoln, NE),
and an Odyssey imager (LI-COR Biosciences, Lincoln, NE) with known concentrations of
purified gC protein used to generate a standard curve for quantification.
HSV-1 infection of immunocompromised mice
Mice were injected intraperitoneally with 300mg/kg cyclophosphamide. One day later, mice
were depilated. Two days after cyclophosphamide injection, mice were infected with 105
HSV-1 by scarification with 25G needles. Mice were photographed once daily, and lesion
sizes were quantified using ImageJ. Mice were euthanized when they became extremely
lethargic and/or exhibited signs of paralysis, indicating systemic spread of the virus and
imminent mortality.
Proximity Ligation Assay
NHEK seeded into chamberslides (Thermo Fisher Scientific, Waltham, MA) were incubated
with HSV-1 or gC for 2 hours at 4°C allowing binding, but not internalization. Unbound
virus or protein was removed by washing with cold PBS. Cells were fixed with PFA at 4°C.
Blocking buffer (O-link Bioscience, Uppsala, Sweden) was used to prevent non-specific
antibody binding, and cells were incubated with two primary antibodies (1μg/ml), one
recognizing gC and the other recognizing the indicated proteins, MARCO, Syndecan-1,
OLR1, and SCARA3. Secondary antibodies conjugated with oligonucleotides were added,
and hybridization, ligation, amplification, and detection steps were performed according to
manufacturer's instructions (O-link Bioscience, Uppsala, Sweden) to generate an amplified
fluorescent signal in areas where the antigens recognized by the two primary antibodies
reside within less than approximately 40nm. Fluorescent PLA signals were evaluated using
fluorescence microscopy (described above).
Statistical Analysis
Analyses were performed using GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego, California, USA, www.graphpad.com.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Scavenger receptor ligands inhibit HSV-1 infection of keratinocytes
a, HaCats were treated with 100μg/ml Poly(I:C), or 50μg/ml of Poly(I) or Poly(C) 20
minutes before the addition of HSV-1 at an MOI of 0.01. Cells were incubated for 5.5 hours
before quantification of HSV-1 mRNA by qPCR. b, NHEK were treated with 10μg/ml
Poly(I), Poly(C) and Poly(I:C) for 3 hours before qPCR analysis of gene expression. c,
NHEK were treated with 10μg/ml of the indicated compounds for 20 min prior to the
addition of HSV-1 at an MOI of 0.0005. PFU were quantified 48 hours after infection. d,
NHEK were treated with 10μg/ml Poly(I) or heparin 20 min before infection with WT
HSV-1 at an MOI of 0.0005 or an equivalent amount of HSV-1 gCΔC5/P (HSV-1
possessing gC with a deletion of the heparin binding domain, amino acids 33-123) viral
particles. PFU were quantified 48 hours after infection. PFU are displayed as relative %
compared to untreated cells for each virus. NS, not significant. a-d, all data are means ±
s.e.m, n=3 from representative experiments repeated at least two times. One-way ANOVA
with Tukey post-tests were used for statistical analysis, ** P<0.01; *** P<0.001. b,c, P
values were derived from comparisons to vehicle treated samples.
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Figure 2. Effect of scavenger receptor ligands on adsorption of HSV-1 and purified gC
a, HaCat keratinocytes were incubated with HSV-1 at an MOI of 100 at 4°C with the
indicated concentrations of Poly(I) and Poly(C). Bound HSV-1 was visualized by
fluorescence microscopy. Five images of bound HSV-1 per concentration were captured and
the number of HSV-1 particles quantified using ImageJ. Each image contained 15-20 cells.
Error bars indicate s.e.m. Two-way ANOVA with bonferroni post-tests was used to compare
the effect of Poly(I) to Poly(C). n=5, *** P<0.001. b, purified gC was incubated with NHEK
in the presence of 100μg/ml heparin, Poly(I), or Poly(C) at 4°C. Unbound gC was removed
by multiple wash steps, then cells were fixed and bound gC was detected and quantified
using an on-cell western assay. Error bars indicate s.e.m. One-way ANOVA with Tukey
post-tests were used for statistical analysis with comparisons made to vehicle treated cells,
n=2, ** P<0.01. ND, not detectable, NS, not significant. c,d, 100μg of purified gC was
bound to a Heparin column, and eluted with a linear gradient (broken line) of Poly(I) (c), or
NaCl (d). Eluted gC was quantified from 1ml fractions by dot blot and plotted as solid black
circles representing each individual fraction connected by a solid line.
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Figure 3. MARCO co-localizes with HSV-1 gC on the keratinocyte cell surface
NHEK were incubated in the presence of purified HSV-1 gC for 2 hours at 4°C to allow
binding of the glycoprotein to the cell surface. Unbound gC was removed by multiple wash
steps before cells were fixed and incubated with both a mouse monoclonal antibody
targeting HSV-1 gC, and rabbit polyclonal antibodies targeting MARCO (a), syndecan-1
(b), OLR1 (c) or SCARA3 (d). Physical proximity of MARCO, syndecan-1, OLR1 or
SCARA3 to HSV-1 gC bound to the cell surface was determined using a fluorescence-based
proximity ligation assay that produces a red fluorescent signal only when the antigens
recognized by the antibodies utilized in the assay reside within less than 40nm of each other.
Nuclei (blue) are stained with Hoescht. Scale bar = 100μm. All data are from representative
experiments repeated 2-4 times.
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Figure 4. MARCO binds directly to HSV-1 gC
Plate-bound purified MARCO protein was incubated with increasing concentrations of
purified gC (a), gB (c) or gCΔC5/P (gC with a deletion of the heparin binding domain,
amino acids 33-123) (e). gC, gB, and gCΔC5/P remaining bound after multiple wash steps
was detected and quantified by ELISA. The dissociation constant (KD) and the maximum
number of receptor binding sites (Bmax) were determined using nonlinear regression with
background subtracted using Graphpad Prism. In (b) and (f), data in (a) and (e),
respectively, were transformed to create double-reciprocal plots to show linear binding
kinetics. d, plate-bound recombinant OLR-1 was incubated with purified gC. gC remaining
bound after washing was detected and quantified by ELISA. a-f, all individual replicate
values plotted with offset overlapping points. All data are from representative experiments
repeated at least two times.
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Figure 5. HSV-1 infection correlates with MARCO expression in cells and in mice and is reduced
by Poly(I)
a-d, HaCat cells were transfected with a control plasmid, pcDNA3 or a pcDNA3-backbone
plasmid with the human MARCO gene inserted (labeled as [MARCO] on graphs) and
selected with G418 to enable stable expression. MARCO and GAPDH protein levels were
visualized in the same sample of 20μg total protein using two-color western blot (a). The
image in (a) is from one representative Western blot of two blots, and the image of the full-
length blot is presented in Supplementary Fig. S4. MARCO protein levels relative to
GAPDH were quantified using Licor Odyssey software (b), n=2, error bars indicate the
s.e.m. c,d, pcDNA3 and [MARCO] cells were infected with WT or HSV-1 gC null (HSV-1
lacking gC) at an MOI of 0.0005. PFU were quantified 48 hours after infection (c) and viral
DNA was quantified 24 hours after infection (d). c,d, comparisons between pcDNA3 and
[MARCO] cells were made using two-tailed T-tests, n=3. Error bars indicate the s.e.m. Data
presented are from one representative experiment of at least two independent experiments. e,
16 week old female mice were immunocompromised with cyclophosphamide prior to
infection with HSV-1. Mice were injected subcutaneously with PBS, or 125μg Poly(C) or
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Poly(I) twice daily at the site of infection beginning the first day of infection. Photographs
were taken once daily beginning the first day post-infection. Lesions were quantified using
ImageJ. Error bars indicate the s.e.m. Two-way ANOVA with bonferroni post-tests was
used to compare wound sizes in Poly(I) and Poly(C) treated mice to PBS treated mice, n=4,
** P<0.01; *** P<0.001. f, 11 week old sex-matched wildtype (WT) and MARCO-/- mice
were immunocompromised with cyclophosphamide prior to infection with HSV-1. Mice
were photographed daily until 8 days post-infection when WT mice began to exhibit
symptoms of systemic and neurological infection, necessitating euthanasia. Lesion
formation was quantified using ImageJ. Error bars indicate the s.e.m. Two-way ANOVA
with bonferroni post-tests was used to compare wound sizes in WT and MARCO-/- mice,
n=5; ** P<0.01. Data presented are from one representative experiment of two independent
experiments.
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